WFRF:(Jörneskog Gun)
Sökning: WFRF:(Jörneskog Gun) > (2000-2004) > Effect of daltepari...
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
- Kalani, MajidKarolinska Institutet (författare)
Effect of dalteparin on healing of chronic foot ulcers in diabetic patients with peripheral arterial occlusive disease: a prospective, randomized, double-blind, placebo-controlled study.
- Artikel/kapitelEngelska2003
Förlag, utgivningsår, omfång ...
- American Diabetes Association,2003
Nummerbeteckningar
- LIBRIS-ID:oai:gup.ub.gu.se/119209
- https://gup.ub.gu.se/publication/119209URI
- https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-211296URI
- https://lup.lub.lu.se/record/117096URI
- https://doi.org/10.2337/diacare.26.9.2575DOI
- http://kipublications.ki.se/Default.aspx?queryparsed=id:1957893URI
Kompletterande språkuppgifter
- Språk:engelska
Ingår i deldatabas
- SwePubSwePub
Klassifikation
Anmärkningar
- OBJECTIVE: Chronic foot ulcers are a common, severe, and expensive complication threatening life and limb in patients with diabetes. The aim of the present study was to investigate the effect of dalteparin on ulcer outcome in patients with diabetes, peripheral arterial occlusive disease, and chronic foot ulcers. RESEARCH DESIGN AND METHODS: A total of 87 patients were investigated in a prospective, randomized, double-blind, placebo-controlled trial. Participants were randomized to treatment with subcutaneous injection of 5000 units dalteparin (Fragmin, Pharmacia Corporation; n = 44) or an equivalent volume of physiological saline (n = 43) once daily until ulcer healing or for a maximum of 6 months. Ulcer outcome was investigated by evaluating the number of patients 1). who healed with intact skin; 2). in whom the study ulcer was improved, unchanged, or impaired; or 3). who were amputated above or below the ankle level, as compared with control subjects. RESULTS: Two patients, one on dalteparin and one on placebo, dropped out of the study. Ulcer outcome was significantly better (P = 0.042, two-sided chi(2) test for trend) in the dalteparin group (n = 43) compared with the placebo group (n = 42). A total of 29 patients healed with intact skin (n = 14) or decreased the ulcer area >or=50% (n = 15) in the dalteparin group compared with 20 (n = 9 and 11, respectively) in the placebo group. Five patients in each group showed impaired ulcer healing, i.e., the ulcer area increased >or=50%. Two patients in the dalteparin group were amputated compared with eight in the placebo group. Time to healing with intact skin was 17 +/- 8 weeks in the dalteparin group compared with 16 +/- 7 weeks in placebo group (NS). CONCLUSIONS: The results of the present study indicate that dalteparin improves the outcome of chronic foot ulcers in diabetic patients with peripheral arterial occlusive disease.
Ämnesord och genrebeteckningar
- MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Endokrinologi och diabetes hsv//swe
- MEDICAL AND HEALTH SCIENCES Clinical Medicine Endocrinology and Diabetes hsv//eng
- Age of Onset
- Aged
- Aged
- 80 and over
- Arterial Occlusive Diseases
- drug therapy
- Body Mass Index
- Dalteparin
- therapeutic use
- Diabetes Mellitus
- Type 1
- Diabetes Mellitus
- Type 2
- Diabetic Angiopathies
- drug therapy
- Diabetic Foot
- drug therapy
- Double-Blind Method
- Female
- Fibrinolytic Agents
- therapeutic use
- Humans
- Male
- Patient Selection
- Placebos
- Wound Healing
- drug effects
Biuppslag (personer, institutioner, konferenser, titlar ...)
- Apelqvist, JanLund University,Lunds universitet,Genomik, diabetes och endokrinologi,Forskargrupper vid Lunds universitet,Genomics, Diabetes and Endocrinology,Lund University Research Groups(Swepub:lu)endo-jap (författare)
- Blombäck, MargaretaKarolinska Institutet (författare)
- Brismar, KerstinKarolinska Institutet (författare)
- Eliasson, Björn,1959Gothenburg University,Göteborgs universitet,Institutionen för invärtesmedicin,Institute of Internal Medicine(Swepub:gu)xelibj (författare)
- Eriksson, Jan W,1959Uppsala universitet,Gothenburg University,Göteborgs universitet,Institutionen för invärtesmedicin, Avdelningen för internmedicin,Institute of Internal Medicine, Dept of Medicine,Endokrin diabetes och metabolism(Swepub:gu)xerija (författare)
- Fagrell, Bengt (författare)
- Hamsten, AndersKarolinska Institutet (författare)
- Torffvit, OleLund University,Lunds universitet,Medicin, Lund,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Medicine, Lund,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)med-oto (författare)
- Jörneskog, GunKarolinska Institutet (författare)
- Karolinska InstitutetGenomik, diabetes och endokrinologi (creator_code:org_t)
Sammanhörande titlar
- Ingår i:Diabetes care: American Diabetes Association26:9, s. 2575-800149-59921935-5548
Internetlänk
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12941721&dopt=AbstractFULLTEXT
- http://dx.doi.org/10.2337/diacare.26.9.2575FULLTEXT
- http://care.diabetesjournals.org/content/26/9/2575.full.pdf
- https://gup.ub.gu.se/publication/119209
- https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-211296
- https://lup.lub.lu.se/record/117096
- https://doi.org/10.2337/diacare.26.9.2575
- http://kipublications.ki.se/Default.aspx?queryparsed=id:1957893
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
Hitta mer i SwePub
- Av författaren/redakt...
- Kalani, Majid
- Apelqvist, Jan
- Blombäck, Margar ...
- Brismar, Kerstin
- Eliasson, Björn, ...
- Eriksson, Jan W, ...
- visa fler...
- Fagrell, Bengt
- Hamsten, Anders
- Torffvit, Ole
- Jörneskog, Gun
- visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Klinisk medicin
- och Endokrinologi oc ...
- Artiklar i publikationen
- Diabetes care
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
